Clinical Trial

An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-21.
Status change: Not Yet Recruiting → Recruiting 2025-08-26
Trial Details
NCT Number NCT06942143
Lead Sponsor Guangzhou FineImmune Biotechnology Co., LTD.
Collaborators: Sun Yat-Sen University Cancer Center
Conditions Sarcoma, Lung Cancers, Melanoma
Enrollment 15 participants
Start Date 2025-05-22
Primary Completion 2027-04-25 (estimated)
Study Completion 2027-06-25 (estimated)
Updated on ClinicalTrials.gov 2025-09-03